Candel Sets Mid-2027 BLA Plan and Files $50M Stock Program; Shares Sink After Hours
Candel shares fell about 40% in after-hours trading on Nov. 12 after the company set a mid-2027 target for its prostate cancer BLA and filed to sell up to $50 million of stock. It reported $203.1 million in cash.

Candel Therapeutics, Inc. (NASDAQ: CADL) said in an after-hours filing on Nov. 12 that it plans to submit its prostate cancer drug application to the FDA in the middle of 2027. The company reported third-quarter results at 4:05 p.m. ET and filed a prospectus supplement at 4:22 p.m. for up to $50 million of stock sales.
Shares lost about 40% after hours on two filings
Shares traded near $5.00 in after-hours trading, down 40.43% from Thursday's $8.39 close. The two filings landed within about 20 minutes of each other, and it is not clear which one drove the drop. The first regular session that can fully react is Friday, Nov. 13, so the read on the impact is provisional.
Thursday's slide began before the filings
Candel closed at $8.39 on Thursday, down 9.00% from Wednesday's close of $9.22. The regular session fell 7.7% from the pre-market close of $9.09, on 779,086 shares, about 0.74 times the stock's 10-day average pace. The filings came after that session ended, so the daytime decline was not a reaction to them.
Pre-market trading (the session before the 9:30 a.m. open) was thin, with 1,674 shares changing hands at a price 0.97% below Wednesday's after-hours close.
After hours, the stock hit a low of $4.90, and 453,469 shares had traded by 4:53 p.m. ET. The average full-day volume over the past 10 sessions is about 1.2 million shares.
In the sessions from Oct. 14 through Nov. 11, the stock gained 1.65%, with a high of $9.84 on Nov. 9 and a low of $7.70 on Oct. 26. It fell 11.16% on Nov. 5 to $8.04, then closed at $8.75, $9.49, $9.35 and $9.22 over the next four sessions.
What the filings said
Candel reported a third-quarter loss of $0.28 a share. Analysts had expected a loss of $0.35.
A Biologics License Application (BLA) is the formal request for FDA approval to market a drug. The company tied the mid-2027 timing to assay refinement (work on the lab tests used to measure the drug) and said the plan depends on the outcome of its dialogue with the FDA. Candel describes itself as a clinical-stage biopharmaceutical company.
The stock program is an at-the-market offering, meaning the company sells shares gradually on the open market through its sales agent, Jefferies LLC. Candel said it has already sold the full $50 million available under the earlier agreement. The new agreement covers up to another $50 million, with Jefferies taking a 3.0% commission. Sales are made from time to time at prices set by market conditions, and Jefferies is not required to sell any specific amount. Candel's market value was about $651 million.
Cash lasts into 2028 as trial updates continue
- Cash and equivalents were $203.1 million on Sept. 30, which the company said is expected to fund its current operating plan into the second quarter of 2028.
- The company said it is continuing BLA readiness work on manufacturing and clinical sections. A process validation campaign at its contract manufacturer has been run, and the validation batches are in testing.
- At the Society for Immunotherapy of Cancer meeting, the company presented data from a phase 2 prostate trial (PrTK05) showing increases in cytotoxic T cells, a type of immune cell, after treatment.
- Updated phase 1b data for linoserpaturev in recurrent high-grade glioma, a brain cancer, showed median overall survival of 12.0 months in 50 patients given a single administration.
What to watch next
- Friday, Nov. 13: the first full regular session after the filings.
- The outcome of the company's talks with the FDA, which the company says will determine the BLA submission planned for the middle of 2027.
- Whether Candel sells shares under the new $50 million program.
- The biodistribution and shedding data from the PrTK05 trial, which the company said remain on track.
Bottom line
Candel gave a mid-2027 target for its BLA and opened a new $50 million stock-sale program after a session in which shares had already dropped 9.00%. The after-hours price fell about 40% on thin early trading. The quarterly loss came in narrower than analysts expected, and the company reports cash into the second quarter of 2028.
This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.
This article is for informational purposes only and is not investment advice.




